Page 1

November 10 , 2021 MEDEXUS PHARMA Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six - Month Periods Ending September 30 , 2021 Achieved $ 17.9 million revenue driven by continued strength of Rupal ™ Positioned for revenue growth along with expected recovery of IXINITY® sales Commercially launched Trecondy® ( treosulfan ) in Canada Available liquidity of $ 9.6 million Management to host conference call at 8:00 AM Eastern Time on November 11th , 2021 TORONTO and CHICAGO , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) Medexus Pharmaceuticals Inc. ( " Medexus " or the " Company " ) ( TSX : MDP ) ( OTCQX : MEDXF ) today announced its financial results and provided a business update for the three - month period ended September 30 , 2021. All dollar amounts below are in United States dollars unless specified otherwise . Second Quarter Fiscal 2022 Financial Highlights : • Revenue of $ 17.9 million compared to $ 17.8 million for the same period last year . Sales during the quarter were positively impacted by RupallTM sales , which saw unit demand growth of 33 % in the trailing twelve - months ended September 30 , 2021¹ . This growth was partially offset by a decline in ex - factory sales of IXINITY® , when compared to the same quarter last year , while Rasuvo and Metoject continue to make strong contributions to revenue . • Adjusted EBITDA * decreased to ( $ 2.0 ) million compared to $ 2.3 million for the same period last year , due to an increase in research & development costs over the comparative period , and the significant investments the Company made to prepare the expected launch of treosulfan in the US . • Net cash flow outflow of ( $ 2.1 ) million in the period , compared to ( $ 1.1 ) million for the same period last year . • Net income was $ 10.1 million , primarily due to gains on the fair value of derivatives , compared to ( $ 1.6 ) million for the same period last year . • Adjusted Net Income * ( which adjusts for such unrealized losses or gains on the fair value of derivatives ) was ( $ 6.1 ) million compared to ( $ 1.3 ) million for the same period last year . Cash and cash equivalents of $ 8.1 million with $ 9.6 million of available liquidity at